Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
about
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsPeroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attackPeroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attackNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewComparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesCardiovascular safety of anti-diabetic drugsRecent advances in managing and understanding diabetic nephropathyDiabetes Drugs and Cardiovascular SafetyPPARs: Protectors or Opponents of Myocardial Function?Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsIs the cardiovascular system a therapeutic target for cannabidiol?Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapiesTreating the elderly diabetic patient: special considerationsThe risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.After avandia: the use of antidiabetic drugs in patients with heart failurePeroxisome Proliferator-Activated Receptor- γ in Thyroid AutoimmunityWeight control and prevention of metabolic syndrome by green tea.Improvements in the Management of Diabetic NephropathyComparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytesDifferential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort studyRisk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias ToolStudy of Cardiovascular Health Outcomes in the Era of Claims Data: The Cardiovascular Health StudyCardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesObservational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case StudiesValidation of methods for assessing cardiovascular disease using electronic health data in a cohort of Veterans with diabetes.Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection.Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysisPotential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysisRisk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.Differing effects of metformin on glycemic control by race-ethnicity.A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.Rosiglitazone: a European regulatory perspective.Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study.Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts.
P2860
Q22241134-4F441262-1AA4-44D5-8005-A71512300C60Q24186319-EE3989C6-903C-40C7-BE74-8862096503B7Q24201174-E205A200-F4F6-4E2C-A50F-36D15FB29520Q24561401-943238AB-CA2E-48F7-9D61-B2C101C9D48CQ24632655-76572ABB-4092-42B9-8473-652A8BC0D251Q26741082-F1FE2098-D934-4F46-A0DC-97A4CEE6E944Q26745900-9D3DC355-AB0D-4CB8-9FFD-457E4C6873D0Q26746085-01F829B9-5E87-4D70-84A0-2751645CD2CCQ26771753-2B13CBE5-78B5-43E4-8F87-9367FACCB39CQ26829098-605A1A85-7ED3-47C9-8346-7B9F90428AB1Q26865370-98082AA4-9CD9-48D8-94DA-B15AB8DF3A9FQ26866958-A8650F00-49F0-4D57-B3AE-E36C2ED6EE5EQ26995176-A658C677-C228-4306-9814-8A6A91F583BCQ26999933-19CA7654-DCE5-4C18-8B21-2F8B9B421C4FQ27007027-4F293140-C4D5-4835-BACB-4F4B6CDA647DQ27021166-F1A5A714-BED8-4D0E-A257-EEBAF18965B0Q27022369-A247059E-4A13-4EEB-8204-09A1B26C4860Q27687558-BA7A7D22-1AAD-4FDA-B4DC-0BB240FC38A4Q28080717-519114C7-F0A3-4F64-B7A4-E4D21D9DBEA0Q28477796-0511C726-AD58-4400-8560-5818C3E88F5FQ28547367-747D871F-9308-42D5-8B3F-FC94CC5BA119Q28551188-D3B8D356-1029-45A3-82EA-3BD701AFAE7AQ28601636-35D0A0B6-795D-4964-92D9-140CC62D409DQ28741419-251B1030-4240-465D-8B1E-8B98077CB93BQ30538243-7A769041-E762-43F5-A52C-56A5C8934055Q30665207-480910E0-99D5-40F9-A06F-55D5B398A675Q30740532-700161E6-A222-4835-B273-781D85B2BADDQ30876081-3EB101A3-7EA1-4087-B4B5-957090FFC380Q30891396-CB5ADACA-E700-4FE1-8073-B0C2AB49DA40Q33818302-9654E18C-E6FC-41E9-B5E6-6600AD8E15B0Q33961458-D88EAF49-C18B-4773-9DD8-D258611EEF93Q34065266-C3B97F52-2745-4653-B464-FE09C5325FC3Q34099031-12A5FA1F-6BA2-4ADB-B360-38241DCB1788Q34130997-341A82A2-046C-42D9-9E08-2E222BE938F4Q34133971-BC633E3D-CF2F-49A3-82EA-734F8EA4AD98Q34154718-59F8182F-074D-4906-AD2E-D6145F2694DBQ34202989-510EE353-6677-4690-A405-6C907C3088C4Q34259900-3A4B9A0C-4790-45E6-970D-85D23AEEDA79Q34315432-2AD3FD20-6620-4C59-9444-C21FB58EC0A6Q34365179-54D1AA59-BC1D-47CC-AFF8-3684B4800E3E
P2860
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@ast
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@en
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@nl
type
label
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@ast
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@en
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@nl
prefLabel
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@ast
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@en
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@nl
P2093
P921
P356
P1476
Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.
@en
P2093
Christopher Sholley
Christopher Worrall
David J Graham
Farzana Ali
Jeffrey A Kelman
Rita Ouellet-Hellstrom
Thomas E MaCurdy
P304
P356
10.1001/JAMA.2010.920
P407
P577
2010-06-28T00:00:00Z